Orthocell issues new shares after employee option exercise under equity incentive plan

Orthocell Ltd ( (AU:OCC) ) has issued an announcement.

Orthocell Limited has issued 445,696 fully paid ordinary shares following the cashless exercise of 1,050,000 employee options under its Employee Equity Incentive Scheme, priced at $0.515 per option and expiring in May 2026. The company has lodged the required notice under section 708A(5)(e) of the Corporations Act, confirming the shares were issued without a prospectus but may be traded immediately under the on-sale exemption, and that Orthocell remains compliant with its continuous disclosure and reporting obligations with no excluded information to disclose.

The move modestly increases Orthocell’s share base while reinforcing the role of equity incentives in aligning employees with shareholder interests as the company advances its regenerative medicine portfolio. Immediate tradability of the new shares ensures liquidity for participating employees and signals regulatory compliance and transparency to investors, supporting confidence as Orthocell progresses commercialisation of its products across key international markets.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.24 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

More about Orthocell Ltd

Orthocell Limited is an Australian regenerative medicine company focused on restoring mobility through products that repair bone and soft tissue injuries. Its portfolio includes collagen-based medical devices used in dental and orthopaedic reconstruction, such as Striate+ for dental guided bone regeneration, which is cleared in major markets including the U.S., Europe and Brazil and distributed globally by BioHorizons Implant Systems Inc. Orthocell also markets Remplir for peripheral nerve reconstruction, with approvals across the U.S., Australia, New Zealand, Singapore, Canada, Hong Kong and Thailand, and offers SmrtGraft for tendon repair in Australia under special access and clinical trial pathways, alongside autologous cell therapies targeting damaged tendon and cartilage tissue.

Average Trading Volume: 410,417

Technical Sentiment Signal: Hold

Current Market Cap: A$244.2M

Find detailed analytics on OCC stock on TipRanks’ Stock Analysis page.